Hepatic and serum <scp>branched‐chain</scp> fatty acid profile in patients with <scp>nonalcoholic</scp> fatty liver disease: A <scp>case–control</scp> study

Martínez‐Montoro, José Ignacio; Núñez‐Sánchez, María Ángeles; Martínez-Sánchez, María Antonia; Balaguer-Román, Andrés; Fernández-Ruiz, Virginia E.; Ferrer-Gómez, Mercedes; Śledziński, Tomasz; Frutos, María Dolores; Fernández‐García, José Carlos; Mika, Adriana; Ramos‐Molina, Bruno

doi:10.1002/oby.23711

Cited by 9 publications

(5 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, the BLCFA level returns to normal 6–9 months after surgery . However, BLCFA levels increase significantly in the liver of NAFLD patients . But whether this increase is the effect of the liver disease or the cause of the disease needs further investigation.…”

Section: Biological Activities Of Blcfamentioning

confidence: 97%

“…77 However, BLCFA levels increase significantly in the liver of NAFLD patients. 78 But whether this increase is the effect of the liver disease or the cause of the disease needs further investigation. Serum total iso-BLCFA are negatively correlated with circulating TAG and hepatic stearoyl-coenzyme A desaturase 1 (SCD1) activity in overweight patients, suggesting a possible role of BLCFA in regulating lipid metabolism.…”

Section: Lipid-lowering Activitymentioning

confidence: 99%

See 1 more Smart Citation

Branched-Long-Chain Monomethyl Fatty Acids: Are They Hidden Gems?

Mao,

Liu,

Tian

et al. 2023

J. Agric. Food Chem.

View full text Add to dashboard Cite

Section: Biological Activities Of Blcfamentioning

confidence: 97%

Section: Lipid-lowering Activitymentioning

confidence: 99%

Branched-Long-Chain Monomethyl Fatty Acids: Are They Hidden Gems?

Mao,

Liu,

Tian

et al. 2023

J. Agric. Food Chem.

View full text Add to dashboard Cite

“…These participants were enrolled consecutively in this period. Results from this cohort have been previously published, and more details can be found elsewhere [22,23].…”

Section: Study Design and Participantsmentioning

confidence: 99%

“…The collection and processing of intraoperative liver biopsy samples from patients undergoing metabolic surgery have been described previously [22,23]. Expert liver pathologists from Virgen the la Arrixaca University Hospital and the Experimental Pathology of the Biomedical Research Institute of Murcia evaluated and scored liver biopsies.…”

Section: Liver Biopsies Collection and Processingmentioning

confidence: 99%

Triglyceride to HDL Cholesterol Ratio for the Identification of MASLD in Obesity: A Liver Biopsy-Based Case-Control Study

Martínez-Montoro,

Martínez-Sánchez,

Balaguer-Román

et al. 2024

Nutrients

Self Cite

View full text Add to dashboard Cite

Associations between dyslipidemia and metabolic dysfunction-associated steatotic liver disease (MASLD) have been reported. Previous studies have shown that the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio may be a surrogate marker of MASLD, assessed by liver ultrasound. However, no studies have evaluated the utility of this ratio according to biopsy-proven MASLD and its stages. Therefore, our aim was to evaluate if the TG/HDL-C ratio allows for the identification of biopsy-proven MASLD in patients with obesity. We conducted a case-control study in 153 patients with obesity who underwent metabolic surgery and had a concomitant liver biopsy. Fifty-three patients were classified as no MASLD, 45 patients as metabolic dysfunction-associated steatotic liver—MASL, and 55 patients as metabolic dysfunction-associated steatohepatitis—MASH. A receiver operating characteristic (ROC) analysis was performed to assess the accuracy of the TG/HDL-C ratio to detect MASLD. We also compared the area under the curve (AUC) of the TG/HDL-C ratio, serum TG, and HDL-C. A higher TG/HDL-C ratio was observed among patients with MASLD, compared with patients without MASLD. No differences in the TG/HDL-C ratio were found between participants with MASL and MASH. The greatest AUC was observed for the TG/HDL-C ratio (AUC 0.747, p < 0.001) with a cut-off point of 3.7 for detecting MASLD (sensitivity = 70%; specificity = 74.5%). However, no statistically significant differences between the AUC of the TG/HDL-C ratio and TG or HDL-C were observed to detect MASLD. In conclusion, although an elevated TG/HDL-C ratio can be found in patients with MASLD, this marker did not improve the detection of MASLD in our study population, compared with either serum TG or HDL-C.

show abstract

“…The determination of fatty acids was performed as outlined in Supplementary materials and methods and as described previously [18,19].…”

Section: Analysis Of Fatty Acid Levels In Human Liver Tissue By Gas C...mentioning

confidence: 99%

Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction‐associated steatotic liver disease

Núñez‐Sánchez,

Martínez‐Sánchez,

Sierra‐Cruz

et al. 2024

The Journal of Pathology

Self Cite

View full text Add to dashboard Cite

Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a chronic liver condition that often progresses to more advanced stages, such as metabolic dysfunction‐associated steatohepatitis (MASH). MASH is characterized by inflammation and hepatocellular ballooning, in addition to hepatic steatosis. Despite the relatively high incidence of MASH in the population and its potential detrimental effects on human health, this liver disease is still not fully understood from a pathophysiological perspective. Deregulation of polyamine levels has been detected in various pathological conditions, including neurodegenerative diseases, inflammation, and cancer. However, the role of the polyamine pathway in chronic liver disorders such as MASLD has not been explored. In this study, we measured the expression of liver ornithine decarboxylase (ODC1), the rate‐limiting enzyme responsible for the production of putrescine, and the hepatic levels of putrescine, in a preclinical model of MASH as well as in liver biopsies of patients with obesity undergoing bariatric surgery. Our findings reveal that expression of ODC1 and the levels of putrescine, but not spermidine nor spermine, are elevated in hepatic tissue of both diet‐induced MASH mice and patients with biopsy‐proven MASH compared with control mice and patients without MASH, respectively. Furthermore, we found that the levels of putrescine were positively associated with higher aspartate aminotransferase concentrations in serum and an increased SAF score (steatosis, activity, fibrosis). Additionally, in in vitro assays using human HepG2 cells, we demonstrate that elevated levels of putrescine exacerbate the cellular response to palmitic acid, leading to decreased cell viability and increased release of CK‐18. Our results support an association between the expression of ODC1 and the progression of MASLD, which could have translational relevance in understanding the onset of this disease. © 2024 The Pathological Society of Great Britain and Ireland.

show abstract

Hepatic and serum branched‐chain fatty acid profile in patients with nonalcoholic fatty liver disease: A case–control study

Cited by 9 publications

References 53 publications

Branched-Long-Chain Monomethyl Fatty Acids: Are They Hidden Gems?

Branched-Long-Chain Monomethyl Fatty Acids: Are They Hidden Gems?

Triglyceride to HDL Cholesterol Ratio for the Identification of MASLD in Obesity: A Liver Biopsy-Based Case-Control Study

Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction‐associated steatotic liver disease

Contact Info

Product

Resources

About